Galapagos (company)
| Galapagos NV | |
|---|---|
| legal form | NV |
| ISIN | BE0003818359 |
| founding | 1999 |
| Seat |
Mechelen , Belgium
|
| management | Onno van de Stolpe ( CEO ) Raj Parekh (Chairman of the Board) |
| Number of employees | 725 |
| sales | 318 million euros |
| Branch | Pharmaceutical research |
| Website | www.glpg.com |
| As of December 31, 2018 | |
The Galapagos NV is a Belgian company in the field of drug discovery . The company was founded in 1999 as a joint venture between the two pharmaceutical companies Crucell and Tibotec . In May 2005 the company went public on the Euronext stock exchanges in Amsterdam and Brussels and is now part of the AEX index , the BEL20 index and the Euronext 100 index . In 2014, Galapagos sold parts of the company to Charles River Laboratories and henceforth concentrated on the existing drug development in the product pipeline .
Individual evidence
- ^ Galapagos: Board of Directors , accessed September 19, 2018
- ↑ a b Galapagos: Annual Report 2018 (English), accessed on May 20, 2019
- ^ Galapagos: Our History , accessed September 19, 2018
- ↑ outsourcing-pharma.com: CRL to buy Argenta and Biofocus from Galapagos for € 134m (English), accessed on September 19, 2018